UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Medline ® Abstract for Reference 54

of 'Systemic treatment for unresectable malignant pleural mesothelioma'

54
TI
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
AU
Scherpereel A, Mazieres J, Greillier L, et al
SO
J Clin Oncol. 2017;35S(ASCO):LBA8507.
 
AD